EVOLVE Short DAPT Study: A prospective, multicenter, single-arm study designed to assess the safety 3-month of dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with the SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)
A study for patients diagnosed with coronary artery disease using the SYNERGY Stent System
Sponsor: Boston Scientific
Enrolling: Male and Female Patients
IRB Number: AAAQ6150
U.S. Govt. ID: NCT02605447
Contact: Lauren Privitera: 212-342-3488 / lp2183@cumc.columbia.edu
Additional Study Information: The purpose of this research is to find out whether it is safe to shorten the length of time that people at high risk for bleeding take blood thinners after being treated with a coronary stent.
This study is closed
Investigator
Manish Parikh, MD
Do You Qualify?
Have you been diagnosed with coronary arterial disease? Yes No
Do you require a coronary stent? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Lauren Privitera
lp2183@cumc.columbia.edu
212-342-3488
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE